GlassScriptPhysician profile
Meagan Nowlan
NPI 1811579717
$1,064.63
in general payments reported to CMS, 2019-2025
20 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $122 · 2023: $130 · 2024: $219 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $148.09 | 2021-2025 | Breztri |
| Abbvie INC. | $133.28 | 2022-2025 | |
| Novo Nordisk INC | $119.49 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $115.75 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $83.19 | 2024 | Xarelto |
| Amgen INC. | $80.16 | 2023-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $74.97 | 2025 | Rexulti |
| Lilly USA, LLC | $51.35 | 2023-2025 | Zepbound, Mounjaro |
| Vanda Pharmaceuticals INC. | $49.64 | 2025 | Fanapt |
| Abbott Laboratories | $41.12 | 2024-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $19.97 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $19.37 | 2025 | |
| Radius Health, INC. | $19.21 | 2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.47 | 2025 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $16.55 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $16.23 | 2025 | Omnipod |
| Global Blood Therapeutics, INC. | $15.69 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.35 | 2022 | |
| Merck Sharp & Dohme LLC | $13.84 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Nowlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.